Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Amylyx Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered(1) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||
| Equity | Common stock, par value $0.0001 per share | 457(c) and 457(h) | 750,000(2) | $22.00(3) | $16,500,000 | 0.00011020 | $1,818.30 | |||||||
| Total Offering Amounts | $16,500,000 | $1,818.30 | ||||||||||||
| Total Fee Offsets | $0 | |||||||||||||
| Net Fee Due | $1,818.30 | |||||||||||||
| (1) | In accordance with Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued under the Amylyx Pharmaceuticals, Inc. 2023 Inducement Plan (the “Plan”) to prevent dilution resulting from stock splits, stock dividends, recapitalization or similar transactions that result in an increase in the number of outstanding securities. |
| (2) | Represents shares of Common Stock that may become issuable under the Plan pursuant to its terms. |
| (3) | Estimated in accordance with Rules 457(c) and 457(h) under the Securities Act, solely for the purpose of computing the amount of the registration fee, on the basis of the average of the high and low prices of shares of the registrant’s common stock, par value $0.0001 per share (“Common Stock”), reported on the Nasdaq Global Select Stock Market on August 7, 2023, which is within five business days of this filing. |
